Literature DB >> 3791557

Protein binding of five platinum compounds. Comparison of two ultrafiltration systems.

W J van der Vijgh, I Klein.   

Abstract

Amicon Centriflo CF50A cones and Amicon MPS-1 micropartition systems with YMT filters were compared for the preparation of ultrafiltrates of plasma samples containing cisplatin, spiroplatin, JM-40, carboplatin or iproplatin. The MPS-1 system equipped with YMT membranes showed less adsorption of the platinum compounds than CF50A cones and allowed more rapid processing of smaller plasma volumes. In vitro binding to human plasma proteins measured with YMT filters after 24 h of incubation was 94%, 89%, 83%, 31% and 0 for cisplatin, spiroplatin, JM-40, carboplatin and iproplatin, respectively. These values corresponded with the initial half-lives in plasma and the decomposition half-lives of intact drug in plasma ultrafiltrate as measured by HPLC. It is suggested that the degree of protein binding is related to the stability of the leaving groups.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3791557     DOI: 10.1007/bf00262281

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  11 in total

Review 1.  The role of cis-platinum in solid-tumor therapy.

Authors:  L H Einhorn; S D Williams
Journal:  N Engl J Med       Date:  1979-02-08       Impact factor: 91.245

2.  cis-Dichlorodiammineplatinum(II) stability in aqueous vehicles: an alternate view.

Authors:  A J Repta; D F Long; A A Hincal
Journal:  Cancer Treat Rep       Date:  1979-02

3.  On-line differential pulse polarographic detection of carboplatin in biological samples after chromatographic separation.

Authors:  F Elferink; W J van der Vijgh; H M Pinedo
Journal:  Anal Chem       Date:  1986-09       Impact factor: 6.986

Review 4.  New platinum complexes in clinical trials.

Authors:  F H Lee; R Canetta; B F Issell; L Lenaz
Journal:  Cancer Treat Rev       Date:  1983-03       Impact factor: 12.111

5.  In vitro interactions of TNO6 with human plasma.

Authors:  B Hecquet; L Adenis; A Demaille
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Monitoring the reactions of cisplatin with nucleotides and methionine by reversed-phase high-performance liquid chromatography using cationic and anionic pairing ions.

Authors:  C M Riley; L A Sternson; A J Repta; S A Slyter
Journal:  Anal Biochem       Date:  1983-04-01       Impact factor: 3.365

7.  In vitro plasma binding of some second generation antitumor platinum complexes.

Authors:  R Momburg; M Bourdeaux; M Sarrazin; F Roux; C Briand
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jan-Mar       Impact factor: 2.441

8.  Phosphate buffer and salt medium concentrations affect the inactivation of T4 phage by platinum(II) complexes.

Authors:  H B Pedersen; J Josephsen; G Kerszman
Journal:  Chem Biol Interact       Date:  1985-06       Impact factor: 5.192

9.  Determination of ethylenediamineplatinum(II) malonate in infusion fluids, human plasma and urine by high-performance liquid chromatography.

Authors:  W J van der Vijgh; F Elferink; G J Postma; J B Vermorken; H M Pinedo
Journal:  J Chromatogr       Date:  1984-10-12

10.  Analysis of antitumour [1,1-bis(aminomethyl)cyclohexane]platinum(II) complexes derived from spiroplatin by high-performance liquid chromatography with differential pulse amperometric detection.

Authors:  F Elferink; W J van der Vijgh; H M Pinedo
Journal:  J Chromatogr       Date:  1985-03-01
View more
  18 in total

1.  Chemical reactivity of cisplatin bound to human plasma proteins.

Authors:  L Hegedüs; W J van der Vijgh; I Klein; S Kerpel-Fronius; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Cerebrospinal fluid pharmacokinetics of carboplatin in children with brain tumors.

Authors:  R Riccardi; A Riccardi; C Di Rocco; G Carelli; R L Tartaglia; A Lasorella; T Servidei; R Mastrangelo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin.

Authors:  R C Gaver; A M George; G Deeb
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 4.  Platinum antitumour agents: a review of (bio)analysis.

Authors:  T J Hodes; W J Underberg; G Los; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

5.  Effects of storage on the binding of carboplatin to plasma proteins.

Authors:  K Erkmen; M J Egorin; L M Reyno; R Morgan; J H Doroshow
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 6.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

7.  Stability of the new anticancer platinum analogue 1,2-diaminomethyl-cyclobutane-platinum(II)-lactate (lobaplatin; D19466) in intravenous solutions.

Authors:  H J Guchelaar; D R Uges; P Aulenbacher; E G de Vries; N H Mulder
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

8.  Pharmacokinetics of carboplatin after intraperitoneal administration.

Authors:  F Elferink; W J van der Vijgh; I Klein; W W ten Bokkel Huinink; R Dubbelman; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Comparative distribution and excretion of carboplatin and cisplatin in mice.

Authors:  Z H Siddik; M Jones; F E Boxall; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Pharmacokinetics of (1R,2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits.

Authors:  R Kizu; S Higashi; Y Kidani; M Miyazaki
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.